Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Change in Account Payables (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Change in Account Payables for 7 consecutive years, with -$1.5 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 195.25% to -$1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Dec 2025, down 543.0% year-over-year, with the annual reading at -$2.0 million for FY2025, 543.0% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$1.5 million at Kymera Therapeutics, down from -$267000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $4.2 million in Q3 2022, with the low at -$4.1 million in Q2 2025.
  • Average Change in Account Payables over 5 years is $3200.0, with a median of -$206000.0 recorded in 2021.
  • Peak annual rise in Change in Account Payables hit 5122.67% in 2025, while the deepest fall reached 13432.26% in 2025.
  • Over 5 years, Change in Account Payables stood at -$1.0 million in 2021, then plummeted by 101.17% to -$2.1 million in 2022, then soared by 174.03% to $1.5 million in 2023, then tumbled by 132.98% to -$505000.0 in 2024, then plummeted by 195.25% to -$1.5 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$1.5 million, -$267000.0, and -$4.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.